methyl 1-(cyclopentylcarbonyl)cyclohexanecarboxylate | 60433-01-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: methyl 1-(cyclopentylcarbonyl)cyclohexanecarboxylate
• 英文别名: Methyl 1-(cyclopentylcarbonyl)cyclohexane-carboxylate；methyl 1-(cyclopentanecarbonyl)cyclohexane-1-carboxylate
• CAS: 60433-01-4
• 化学式: C₁₄H₂₂O₃
• 分子量: 238.327
• InChiKey: DGTVEVYAXHTXKG-UHFFFAOYSA-N

物化性质

• 沸点：
  330.6±25.0 °C(Predicted)
• 密度：
  1.090±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 1-(cyclopentylcarbonyl)cyclohexanecarboxylate 在 溴 作用下， 以 溶剂黄146 为溶剂， 以86%的产率得到methyl 1-(1-bromocyclopentylcarbonyl)cyclohexanecarboxylate
  参考文献：
  名称：

  Synthesis of 6-Aryltetrahydropyran-2,4-diones Containing Tetra- and Pentamethylene Substituents in the 3 and 5 Positions of the Heteroring

  摘要：

  Methyl esters of 1-(1-bromocyclopentylcarbonyl)- and 1-(1-bromocyclohexylcarbonyl)cyclopentanecarboxylic or 1-(1-bromocyclopentylcarbonyl)cyclohexanecarboxylic acids react with zinc and aromatic aldehydes to form 14-aryl-13-oxadispiro[4.1.4.3]tetradecane-6,12-diones, 13-aryl-14-oxadispiro[4.1.5.3]pentadecane-6,15-diones, and 15-aryl-14-oxadispiro[4.1.5.3]pentadecane-6,13-diones, respectively.

  DOI：

  10.1023/b:rugc.0000042430.44366.01
• 作为产物：
  描述：

  环戊基甲酰氯 、 1-溴环己烷羧酸甲酯 在 锌 作用下， 以 乙酸乙酯 、 苯 为溶剂， 以58%的产率得到methyl 1-(cyclopentylcarbonyl)cyclohexanecarboxylate
  参考文献：
  名称：

  Synthesis of 6-Aryltetrahydropyran-2,4-diones Containing Tetra- and Pentamethylene Substituents in the 3 and 5 Positions of the Heteroring

  摘要：

  Methyl esters of 1-(1-bromocyclopentylcarbonyl)- and 1-(1-bromocyclohexylcarbonyl)cyclopentanecarboxylic or 1-(1-bromocyclopentylcarbonyl)cyclohexanecarboxylic acids react with zinc and aromatic aldehydes to form 14-aryl-13-oxadispiro[4.1.4.3]tetradecane-6,12-diones, 13-aryl-14-oxadispiro[4.1.5.3]pentadecane-6,15-diones, and 15-aryl-14-oxadispiro[4.1.5.3]pentadecane-6,13-diones, respectively.

  DOI：

  10.1023/b:rugc.0000042430.44366.01

文献信息

• [EN] CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS<br/>[FR] CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZABENZO[E]AZULÈNES UTILISÉS COMME ANTAGONISTES DES V1A
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013050334A1

  公开（公告）日：2013-04-11

  The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明提供了4H,6H-5-氧杂-2,3,10b-三唑-苯并[e]吖啶衍生物，它们作为V1a受体调节剂，特别是作为V1a受体拮抗剂，它们的制造方法，含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂在末梢和中央条件下对痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、不适当的抗利尿激素分泌、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和攻击性行为是有用的。
• Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US20140221350A1

  公开（公告）日：2014-08-07

  The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明提供了4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]吖啶，其作为V1a受体调节剂，特别是作为V1a受体拮抗剂，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物在治疗作用上在经前痛、男性或女性性功能障碍、高血压、慢性心力衰竭、抗利尿素的不当分泌、肝硬化、肾病综合征、焦虑、抑郁症、强迫性障碍、自闭症谱系障碍、精神分裂症和攻击性行为等疾病中有用。
• Effect of Spiro Ring Size on the Photochemical Ring Expansion of Dispiro Substituted Cyclobutane-1,3-diones
  作者：Koji Kimura、Masakazu Takamura、Shigeru Koshibe、Masayoshi Juro、Yoshihiro Fukuda、Yoshinobu Odaira

  DOI：10.1246/bcsj.49.741

  日期：1976.3

  The photochemical ring expansion of dispiro substituted cyclobutane-1,3-diones in methanol has been investigated. The formation of ring expansion product was strongly dependent on the spiro ring size of dispiro substituent. The ring expanded acetal was obtained in a low yield when the spiro ring of dispiro substituted cyclobutane-1,3-diones was a five- or seven-membered ring. This is the first example

  研究了二螺取代的环丁烷-1,3-二酮在甲醇中的光化学扩环。扩环产物的形成强烈依赖于二螺取代基的螺环尺寸。当双螺取代的环丁烷-1,3-二酮的螺环为五元环或七元环时，扩环缩醛的收率较低。这是环丁烷-1,3-二酮光化学扩环的第一个例子。假设了一种机制。
• CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2763997A1

  公开（公告）日：2014-08-13
• US9346824B2
  申请人：——

  公开号：US9346824B2

  公开（公告）日：2016-05-24